myeloid leukemia

Vor Biopharma Inc (NASDAQ: VOR) has collaborated with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ). Under the terms of the collaboration, Vor Biopharma will investigate the combination of Vor's engineered hematopoietic stem cell (eHSC) platform with...

The European Commission has approved AbbVie Inc's (NYSE: ABBV) Venclyxto (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML). Venclyxto is approved in combination with a hypomethylating agent, azacitidine or decitabine, in AML...

Fate Therapeutics Inc (NASDAQ: FATE) has announced interim data from Phase 1 data from the Company's off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute myeloid leukemia (AML). Data come from two Phase 1 dose-escalation studies that...

Bio-Path Holdings Inc (NASDAQ: BPTH) has completed the safety run-in of Stage 2 of the Phase 2 study evaluating prexigebersen to treat acute myeloid leukemia (AML) in combination with frontline therapies, decitabine and venetoclax. The safety run-in comprised six evaluable patients...

Shares of Celator Pharmaceuticals Inc (NASDAQ: CPXX) tumbled more than 3 percent on Monday after TheStreetSweeper's Sonya Colberg published a scathing report on the company. According to Colberg, the clinical-stage bio-pharmaceutical company has "finished cherry-picking and left the ladder against...